CINECA IRIS Institutional Research Information System

CONCA, VERONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.096
NA - Nord America 1.096
EU - Europa 726
SA - Sud America 188
AF - Africa 66
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.175
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.059
SG - Singapore 423
IT - Italia 337
CN - Cina 279
HK - Hong Kong 199
BR - Brasile 156
DE - Germania 87
SE - Svezia 59
GB - Regno Unito 51
CI - Costa d'Avorio 34
FR - Francia 33
VN - Vietnam 33
FI - Finlandia 32
KR - Corea 29
IN - India 25
JP - Giappone 25
NL - Olanda 21
PL - Polonia 20
RU - Federazione Russa 19
AT - Austria 15
BD - Bangladesh 13
BG - Bulgaria 13
AR - Argentina 12
CA - Canada 12
ID - Indonesia 12
MX - Messico 12
TR - Turchia 11
ES - Italia 7
LT - Lituania 7
NG - Nigeria 7
ZA - Sudafrica 7
SN - Senegal 6
EC - Ecuador 5
IQ - Iraq 5
PH - Filippine 5
PK - Pakistan 5
UA - Ucraina 5
MA - Marocco 4
PE - Perù 4
VE - Venezuela 4
CH - Svizzera 3
CZ - Repubblica Ceca 3
HN - Honduras 3
IE - Irlanda 3
JO - Giordania 3
UZ - Uzbekistan 3
AM - Armenia 2
CL - Cile 2
CO - Colombia 2
DZ - Algeria 2
EG - Egitto 2
GT - Guatemala 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MY - Malesia 2
PA - Panama 2
PT - Portogallo 2
SA - Arabia Saudita 2
TH - Thailandia 2
UY - Uruguay 2
AU - Australia 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CR - Costa Rica 1
DK - Danimarca 1
GD - Grenada 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
KY - Cayman, isole 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
MT - Malta 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TJ - Tagikistan 1
TN - Tunisia 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.175
Salva come PNG Salva come JPEG
Città #
Singapore 217
Hong Kong 191
Ashburn 181
Santa Clara 150
Dallas 148
Shanghai 75
Chandler 74
Los Angeles 64
New York 48
Beijing 44
Florence 41
Boardman 40
Munich 40
Abidjan 34
Hefei 32
Pisa 29
London 26
Seoul 26
Tokyo 21
Cascina 20
Genoa 18
Rome 18
Turku 18
Warsaw 17
São Paulo 16
Turin 16
Fairfield 15
Redondo Beach 15
Frankfurt am Main 13
Lawrence 13
Milan 13
Princeton 13
Sofia 13
Naples 11
Ogden 11
Bremen 10
Helsinki 10
Ho Chi Minh City 10
Medford 10
Nuremberg 10
Vienna 10
Fuzhou 9
Buffalo 7
Gargallo 7
Istanbul 7
Lagos 7
Stockholm 7
Wilmington 7
Dakar 6
Düsseldorf 6
Houston 6
Orem 6
Poplar 6
Bexley 5
Mumbai 5
Quanzhou 5
Atlanta 4
Avaré 4
Chicago 4
Council Bluffs 4
Denver 4
Dhaka 4
Hanoi 4
Jakarta 4
Johannesburg 4
Kent 4
Ottawa 4
Pistoia 4
Qingdao 4
San Diego 4
Toronto 4
Verona 4
Adria 3
Amman 3
Amsterdam 3
Ann Arbor 3
Bari 3
Biên Hòa 3
Bologna 3
Brasília 3
Brooklyn 3
Campo Grande 3
Clifton 3
Coreglia Antelminelli 3
Dublin 3
Guangzhou 3
Haiphong 3
Hyderabad 3
Karachi 3
Lappeenranta 3
Lima 3
Mauá 3
Montreal 3
Nam-gu 3
Osaka 3
Padova 3
Phoenix 3
Phủ Lý 3
Porto Alegre 3
Portsmouth 3
Totale 2.025
Salva come PNG Salva come JPEG
Nome #
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 158
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 142
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients 136
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 131
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability 129
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 111
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 109
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study 105
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 104
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development 102
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 98
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO 96
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers 96
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 89
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies 88
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 88
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 85
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 83
The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients 82
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 80
Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis 80
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study 79
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer 72
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study 66
null 65
Waiting for the "liquid revolution" in the adjuvant treatment of colon cancer patients: a review of ongoing trials 62
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden 61
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience 59
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study 59
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies 59
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer 57
null 57
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 53
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? 52
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies 51
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer 49
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 45
null 44
null 35
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study 19
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study 16
null 15
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO 7
Totale 3.274
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.961
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.961
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022111 0 0 10 1 12 10 1 7 13 5 18 34
2022/2023319 23 45 19 19 29 37 10 18 79 1 33 6
2023/2024409 16 29 53 41 30 48 54 13 17 25 44 39
2024/20251.369 59 41 19 62 108 140 119 69 149 128 177 298
2025/20261.066 166 216 177 159 231 117 0 0 0 0 0 0
Totale 3.274